Off Label Drug Use Data To Be Required In Periodic Safety Updates - FDA
Executive Summary
Pharmaceutical companies will be asked to provide postmarketing drug usage information in their periodic safety update reports, including use in off label indications, under a proposed FDA rule due out later this year.
You may also be interested in...
FDA Plans Three Risk Management-Related Guidances Under PDUFA III
FDA's PDUFA III implementation plan will likely include three separate guidances to cover risk assessment, pharmacovigilance and risk management
FDA Plans Three Risk Management-Related Guidances Under PDUFA III
FDA's PDUFA III implementation plan will likely include three separate guidances to cover risk assessment, pharmacovigilance and risk management
Adverse Drug Event Monitoring Could Include Monthly Literature Reviews
Pharmaceutical companies should review scientific and medical journals at least once a month as part of an adverse event reporting strategy, AstraZeneca VP-Global Drug Safety Barry Arnold said